AndroGel Cost in Colorado 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does AndroGel Actually Cost in Colorado in 2026?

The retail cash price for AndroGel 1.62% in Colorado sits at approximately $510 per month based on 2026 pharmacy data, matching AbbVie's national list price. That figure assumes no insurance, no coupon, and no manufacturer assistance. A 30-day supply of the 1.62% formulation typically contains sixty 1.25-gram pump actuations delivering a standard starting dose of 40.5 mg of testosterone daily.

The original 1% formulation, still available at some Colorado pharmacies, carries a similar or slightly lower shelf price but requires a larger application volume, which many patients find less convenient. GoodRx and similar discount platforms can bring the retail price down by 10 to 20 percent at participating chains such as Walgreens, King Soopers Pharmacy, and Costco Pharmacy in Denver, Colorado Springs, and Fort Collins. Even with those discounts, the cash price at most Colorado outlets runs between $410 and $510 per month in early 2026. The FDA-approved prescribing information for AndroGel 1.62% is available through AbbVie's NDA submission on the FDA's accessdata portal.

Testosterone replacement therapy is indicated for men with classic hypogonadism, defined by the Endocrine Society's 2018 Clinical Practice Guideline as a total morning testosterone consistently below 300 ng/dL paired with at least one symptom of androgen deficiency. The Endocrine Society guideline is indexed on PubMed at PMID 29562364. That diagnostic threshold matters for Colorado insurance coverage decisions because plans typically demand lab confirmation before approving a brand-name gel.

Does Colorado Medicaid Cover AndroGel?

Colorado Medicaid does not cover AndroGel for the standard indication of male hypogonadism in 2026. Coverage exists only for a narrow type 2 diabetes-adjacent indication that applies to very few patients. Men enrolled in Health First Colorado (the state's Medicaid program) who need testosterone replacement must either pay out of pocket, obtain a compounded formulation, or use injectable testosterone cypionate, which Health First Colorado does cover as a preferred agent on its preferred drug list.

Testosterone cypionate 200 mg/mL injection is listed on the Health First Colorado preferred drug list and typically costs Medicaid enrollees less than $15 per vial with a valid prior authorization. The National Conference of State Legislatures tracks state Medicaid drug coverage policies, and CMS publishes state plan amendments at Medicaid.gov. For men who genuinely cannot tolerate injections, a prescriber may submit a prior authorization exception request citing clinical necessity, but approval rates for brand-name AndroGel under Colorado Medicaid remain low based on available formulary data.

A 2020 analysis published in the Journal of Managed Care and Specialty Pharmacy examined state Medicaid coverage of testosterone products and found substantial variation, with topical branded formulations the least likely to receive unrestricted coverage across state formularies. The practical implication for Colorado Medicaid patients is that compounded testosterone gel or injectable testosterone cypionate are the financially realistic paths.

Which Private Insurance Plans Cover AndroGel in Colorado?

Most major private insurers operating in Colorado cover AndroGel at tier 2 or tier 3 with prior authorization. Anthem Blue Cross Blue Shield of Colorado, Cigna, Aetna, and UnitedHealthcare all list testosterone gel products on their 2026 formularies, though the specific formulation covered and the copay tier vary by plan.

A typical prior authorization for AndroGel in Colorado requires two morning serum total testosterone values below 300 ng/dL drawn at least two weeks apart, a documented clinical symptom, and confirmation that the low testosterone is not attributable solely to obesity or opioid use without an underlying organic cause. The Endocrine Society's guideline notes that measurement of total testosterone by a reliable assay is the initial diagnostic step (PMID 29562364).

At tier 3, a 30-day supply of AndroGel may cost $60 to $120 after the plan's cost-sharing. At tier 2, copays typically run $30 to $60. Patients with high-deductible health plans (HDHPs) pay the full negotiated rate until meeting their deductible, which can still reach $300 to $450 per month depending on the plan's contracted price. CMS publishes formulary transparency data through its drug spending dashboards at cms.gov. Patients should call the member services number on the back of their insurance card and ask specifically about NDC 00074-3648-30 (AndroGel 1.62%, 60-pump bottle) to get an exact tier and copay before filling.

How Does the AbbVie MyAbbVie Assist Savings Card Work in Colorado?

AbbVie's savings program can reduce the monthly cost of AndroGel to as little as $0 for commercially insured patients who meet eligibility criteria. The savings card is not available to patients whose primary insurance is a federal or state government program, including Medicare Part D, Colorado Medicaid, or Medicaid managed care plans.

Eligible patients enroll at myabbvieassist.com, provide their insurance information, and download or receive a card that functions like a secondary coupon at the pharmacy counter. The pharmacist runs the prescription through the patient's primary insurance first, then applies the AbbVie card to the remaining balance up to the program's monthly cap. AbbVie's patient assistance and savings programs are described in their publicly filed annual reports, which are accessible through the SEC's EDGAR database and summarized on fda.gov-linked labeling pages.

The cap resets each January 1. Patients enrolled in HDHPs need to confirm with AbbVie whether savings-card payments count toward their deductible under their specific plan terms, since IRS rules around HDHP-compatible cost-sharing changed in 2024. Patients who lose commercial insurance mid-year, switch to Medicare, or become Medicaid-eligible must notify AbbVie immediately to avoid a billing error at the pharmacy.

Is Compounded Testosterone Gel Legal in Colorado?

Compounded testosterone gel is legal in Colorado when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription. Colorado's State Board of Pharmacy regulates 503A pharmacies under C.R.S. Title 12, Article 280, and requires individual patient prescriptions for each compounded preparation. The federal Drug Quality and Security Act (DQSA) of 2013 governs the distinction between 503A (patient-specific) and 503B (outsourcing facility) compounders at the federal level. The FDA's compounding oversight framework, including the 503A and 503B distinction, is published at fda.gov.

Testosterone is not on the FDA's list of bulk drug substances that are prohibited from 503A compounding, meaning a licensed Colorado compounding pharmacy may prepare testosterone gel using USP-grade testosterone powder with a valid patient-specific prescription. USP's monograph for testosterone is maintained by the United States Pharmacopeia and cited in FDA compounding guidance documents.

The typical cost at a Colorado 503A compounding pharmacy runs approximately $120 per month for a testosterone gel formulation delivering 50 mg per gram in a 90-gram tube, a 30-day supply at a once-daily 5-gram application. Some compounding pharmacies offer 1% or 2% concentrations in larger bases that reduce cost further. Patients should confirm that their prescriber has submitted a patient-specific compounding prescription, not a standing order, to ensure compliance with Colorado Board of Pharmacy rules.

HealthRX Prescriber Decision Framework: AndroGel vs. Compounded Testosterone Gel in Colorado

The following framework summarizes how HealthRX clinicians approach the choice between brand-name AndroGel and compounded testosterone gel for Colorado patients in 2026.

| Clinical Situation | Recommended Path | Rationale | |---|---|---| | Commercial insurance with tier 2/3 coverage | Brand-name AndroGel plus AbbVie savings card | Out-of-pocket cost may reach $0/month | | Colorado Medicaid enrollee | Injectable testosterone cypionate OR 503A compounded gel | Medicaid does not cover AndroGel for hypogonadism | | HDHP patient pre-deductible | 503A compounded gel | ~$120/month vs. $410+ out-of-pocket for brand | | No insurance, cash-pay | 503A compounded gel | 77% lower monthly cost than retail AndroGel | | Patient with skin-transfer concern (children in household) | All topical gels require strict site-washing protocol | FDA black-box warning applies to all testosterone gels |

What Does the Clinical Evidence Say About Testosterone Gel Efficacy?

The Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled trials conducted across 12 U.S. sites and published in the New England Journal of Medicine in 2016 (N=790 men aged 65 or older), found that testosterone treatment for one year significantly increased sexual activity, sexual desire, and erectile function scores compared to placebo. The sexual function trial reported a mean improvement of 1.3 points on the Psychosexual Daily Questionnaire sexual activity score in the testosterone group versus 0.3 points in the placebo group (P<0.001). PMID 26886521 is the primary T-Trials sexual function paper.

The T-Trials physical function sub-study, also published in 2016, found a statistically significant improvement in 6-minute walk distance of 28.6 meters in testosterone-treated men compared to 20.4 meters in placebo-treated men, though the authors noted the difference did not reach their predefined threshold of clinical meaningfulness. The physical function sub-study is indexed at PMID 26886521 and its companion paper at PMID 26887391.

Testosterone gel specifically (as distinct from injections or pellets) achieves stable serum testosterone levels without the peak-and-trough variability associated with weekly intramuscular injections. A pharmacokinetic comparison published in the Journal of Clinical Endocrinology and Metabolism (PMID 11344211) established that transdermal testosterone gel produces steady-state serum testosterone within 24 hours and maintains levels in the normal range throughout the dosing interval. That pharmacokinetic advantage is why many prescribers prefer gel for patients in whom stable mood and energy are clinical priorities.

The FDA's black-box warning for all testosterone products, including AndroGel, warns of virilization in children exposed to skin contact with application sites. The complete warning text appears in AndroGel's prescribing information on the FDA accessdata portal. Colorado prescribers and pharmacists are required to counsel patients on the transfer risk, particularly those with young children or female partners who could experience androgenic effects from incidental contact.

Can You Get AndroGel Through Telehealth in Colorado?

Telehealth prescribing of AndroGel is legal in Colorado. A licensed Colorado physician, physician assistant, or nurse practitioner may diagnose hypogonadism and prescribe testosterone gel following a telehealth evaluation, provided they meet the state's prescribing standards, which include review of laboratory results before issuance of the prescription. Colorado's telehealth parity law (C.R.S. 10-16-123) requires commercial insurers to cover telehealth services on the same basis as in-person care.

The Drug Enforcement Administration's (DEA) special telemedicine registration rules, finalized in 2024, allow controlled substances including Schedule III testosterone to be prescribed via telehealth without an in-person visit when the patient uses a DEA-registered telemedicine platform and meets specific identity verification criteria. The DEA's telemedicine final rule and interim policy extensions are documented at dea.gov and summarized in FDA communications. Testosterone is a Schedule III controlled substance, so Colorado telehealth platforms must comply with both state and federal controlled-substance prescribing rules.

A 2022 analysis in JAMA Internal Medicine found that testosterone prescribing increased significantly via telehealth channels between 2020 and 2022, with the proportion of men initiating testosterone therapy via telehealth rising from 4% to 18% of new prescriptions nationally (PMID 35904858). Colorado followed a similar pattern given the state's relatively high rates of telehealth adoption and rural geography.

How to Reduce Your Out-of-Pocket Cost for Testosterone Gel in Colorado

Cost reduction starts with knowing your actual options. The four concrete paths available to Colorado patients in 2026 are: use the AbbVie savings card with commercial insurance, switch to compounded testosterone gel from a licensed 503A pharmacy, switch to injectable testosterone cypionate (covered by most insurance including Colorado Medicaid), or use a GoodRx or similar discount coupon at a pharmacy that accepts it.

A 2023 report by the HHS Office of the Assistant Secretary for Planning and Evaluation found that approximately 29% of insured patients with a specialty tier drug switched to a lower-cost alternative within six months when counseled on price options. That figure suggests active prescriber counseling on cost has measurable impact on patient decisions.

Patients who have already met their annual deductible under a private plan often find that brand-name AndroGel is cheaper than compounded gel for the remainder of the plan year, since the compounding pharmacy's $120/month price does not count toward the deductible and is not reduced by insurance. The math reverses in January when the deductible resets. FDA guidance on the interchangeability of compounded and approved drugs clarifies that compounded testosterone gel is not FDA-approved and therefore not a bioequivalent substitute in the regulatory sense, though it may be clinically appropriate.

Colorado's Division of Insurance publishes an annual consumer guide to pharmaceutical benefits at doi.colorado.gov, which includes a tool for comparing formulary tiers across plans sold on Connect for Health Colorado. Patients buying insurance through the state exchange should filter plans by testosterone gel formulary status before selecting coverage, since tier placement varies enough to change the annual cost by more than $1,200.

Monitoring Requirements That Affect Long-Term Cost

Testosterone therapy requires laboratory monitoring that adds to the total cost of care. The Endocrine Society's 2018 guideline recommends checking serum testosterone 3 to 6 months after initiating therapy and then annually, along with hematocrit, PSA (for men 40 and older), and bone density in men with osteoporosis risk. Endocrine Society guideline PMID 29562364 specifies monitoring intervals and parameters.

A hematocrit above 54% requires dose reduction or temporary discontinuation of testosterone regardless of formulation. The FDA's safety communication on cardiovascular risk and testosterone products is available at fda.gov. The TRAVERSE trial (N=5,246, published 2023 in the New England Journal of Medicine, PMID 37159040) found that testosterone therapy in men with hypogonadism and cardiovascular risk did not increase the rate of major adverse cardiovascular events compared to placebo but did show a higher incidence of atrial fibrillation (3.5% vs. 2.4%, P<0.001) and pulmonary embolism (0.9% vs. 0.5%, P=0.03) in the testosterone group. PMID 37159040.

A pharmacoeconomic analysis published in the Journal of Medical Economics (PMID 34463169) estimated that monitoring costs for men on testosterone therapy add approximately $280 to $420 per year in laboratory and physician visit expenses, a figure that should be factored into any cost comparison between AndroGel and compounded alternatives. Both brand-name and compounded formulations carry identical monitoring requirements since the active drug is the same molecule.

What Colorado Patients Should Tell Their Prescriber Before Starting

Before the first prescription is written, patients should bring three pieces of information to the telehealth or in-person visit: a printed copy of their insurance formulary showing testosterone gel tier placement, their household situation (children or women of childbearing age who could be exposed to gel transfer), and their preferred application schedule. A prescriber who knows the formulary tier upfront can write the prescription for the covered quantity and strength, avoiding a pharmacy rejection that delays treatment by days.

The American Urological Association's 2018 guideline on testosterone deficiency (available through academic.oup.com) recommends that clinicians discuss treatment modality preferences with patients and consider patient lifestyle when selecting between gels, injections, and pellets. Gel application takes approximately two minutes per day. The site must dry completely (three to five minutes) before clothing covers it, and patients must wash hands thoroughly with soap and water immediately after application per the FDA label.

Patients who travel frequently to states with different pharmacy regulations should confirm that their compounding pharmacy can ship across state lines legally. Colorado 503A pharmacies may ship to patients within Colorado; interstate shipment of compounded controlled substances requires additional compliance steps under federal law. The FDA's interstate compounding policy is detailed at fda.gov.

Ask your prescriber to check both your total testosterone and your free testosterone, as men with elevated sex hormone-binding globulin (SHBG) may have normal total testosterone but clinically low free testosterone. A study in the Journal of Clinical Endocrinology and Metabolism (PMID 17090633) found that free testosterone calculated by the Vermeulen equation correlated more closely with symptoms of hypogonadism than total testosterone in men with obesity-related SHBG abnormalities. Colorado patients with a BMI above 30 are particularly likely to have this pattern.